DeepMed Research

Arkansas State University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1909-01-01

Employees: 251

Market Cap: -

Website: http://www.astate.edu

Clinical Trials

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Interim/Maintenance Dexamethasone
Drug: Induction/Consolidation Dexamethasone
Drug: Induction/Consolidation Cisplatin
Drug: Induction/Consolidation Adriamycin
Drug: InductionConsolidation Cyclophosphamide
Drug: Induction/Consolidation Etoposide
Drug: Induction Pegfilgrastim
Drug: Transplant 1 Dexamethasone
Drug: Transplant 1 Cisplatin
Drug: Transplant 1 Adriamycin
Drug: Transplant 1 Cyclophosphamide
Drug: Transplant 1 Etoposide
Drug: Transplant 1 Melphalan
Drug: Transplant 1 and 2 Pegfilgrastim
Procedure: Autologous Peripheral Blood Stem Cell Transplant (ASCT)
Drug: Transplant 2 Carmustine
Drug: Transplant 2 Etoposide
Drug: Transplant 2 Cytarabine
Drug: Transplant 2 Melphalan
Drug: Transplant 2 Dexamethasone
Drug: Transplant 1 and 2 Bortezomib
Drug: Transplant 1 and 2 Thalidomide

First Posted Date: 2007-12-14

Last Posted Date: 2017-11-20

Lead Sponsor: University of Arkansas

Target Recruit Count: 20

Registration Number: NCT00574080

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Glucocorticoids Promote Osteoclast Survival

Terminated

Conditions: Osteoporosis

Interventions: Drug: alendronate

First Posted Date: 2007-12-13

Last Posted Date: 2011-08-30

Lead Sponsor: University of Arkansas

Target Recruit Count: 3

Registration Number: NCT00572299

Locations: 🇺🇸
University of Arkansas hospitals and clinics and the Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States

Therapeutic Research in Multiple Myeloma

Completed

Conditions: Multiple Myeloma

Interventions: Other: No drugs are involved

First Posted Date: 2007-12-13

Last Posted Date: 2015-08-13

Lead Sponsor: University of Arkansas

Target Recruit Count: 6388

Registration Number: NCT00572338

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Axillary Reverse Mapping

Phase 2

Active, not recruiting

Conditions: Cancer of the Breast

Interventions: Procedure: Axillary Reverse Mapping

First Posted Date: 2007-12-13

Last Posted Date: 2024-11-18

Lead Sponsor: University of Arkansas

Target Recruit Count: 1000

Registration Number: NCT00572481

Locations: 🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Thalidomide
Drug: Dexamethasone
Drug: Adriamycin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2007-12-12

Last Posted Date: 2025-03-07

Lead Sponsor: University of Arkansas

Target Recruit Count: 177

Registration Number: NCT00572169

Locations: 🇺🇸
University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas, United States

Effect of Thiazolidinedione Treatment Vascular Risk Markers

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Vascular Diseases

Interventions: Drug: Rosiglitazone
Drug: Pioglitazone

First Posted Date: 2007-12-12

Last Posted Date: 2009-12-09

Lead Sponsor: University of Arkansas

Target Recruit Count: 25

Registration Number: NCT00571506

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation

Phase 1

Completed

Conditions: Cancer of the Breast

Interventions: Device: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)

First Posted Date: 2007-12-12

Last Posted Date: 2015-11-24

Lead Sponsor: University of Arkansas

Target Recruit Count: 107

Registration Number: NCT00571987

Locations: 🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States

Treatment of Oral Premalignant Lesions With 5-ALA PDT

Phase 1

Completed

Conditions: Erythroplakia
Leukoplakia

Interventions: Device: PDL-585, ScleroPLUS laser
Drug: 5-Aminolevulinic Acid (Levulan KerastickTM)
Procedure: Fluorescence Diagnosis Imaging

First Posted Date: 2007-12-12

Last Posted Date: 2015-03-24

Lead Sponsor: University of Arkansas

Target Recruit Count: 29

Registration Number: NCT00571974

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Placebo
Drug: erlotinib

First Posted Date: 2007-12-10

Last Posted Date: 2021-03-30

Lead Sponsor: University of Arkansas

Target Recruit Count: 27

Registration Number: NCT00570258

Locations: 🇺🇸
Hackensack University, Hackensack, New Jersey, United States
🇺🇸
St. Luke's Cancer Institute, Kansas City, Missouri, United States
🇺🇸
NEA Clinic, Jonesboro, Arkansas, United States

and more 3 locations

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Not Applicable

Completed

Conditions: MULTIPLE MYELOMA

Interventions: Drug: Velcade

First Posted Date: 2007-12-10

Last Posted Date: 2011-08-12

Lead Sponsor: University of Arkansas

Target Recruit Count: 11

Registration Number: NCT00569868

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy